Castle Biosciences (CSTL) PT Raised to $31 at Baird, Remains Top Idea
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CSTL Hot Sheet
Price: $35.14 --0%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Baird analyst Catherine Schulte raised the price target on Castle Biosciences (NASDAQ: CSTL) to $31.00 (from $27.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR100 at Piper Sandler
- Apollo Global Management (APO) PT Lowered to $138 at RBC Capital
- Eastman Chemical (EMN) PT Raised to $70 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
